Ajanta Pharma denies reports of acquiring Restaurant Brands Asia
AJANTPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 0.4 pts more than Nifty Midcap 150 and 0.4 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Ajanta Pharma clarified that an Economic Times article linking it to a potential Rs 2,000 crore acquisition of Restaurant Brands Asia is factually incorrect. The company states that a promoter group section managing Lenexis Foodworks Pvt. Ltd. is independently pursuing this acquisition, and Ajanta Pharma Limited and its management are not involved. The company denies the rumours and references a similar earlier clarification made on January 20, 2026.
Removes uncertainty for shareholders; the listed company is not exposed to the restaurant acquisition risk or capital raise being speculated.